Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial by 4Q19 of the

Read the full 390 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE